The Adaptive Platform Trials Coalition. Adaptive platform trials: definition, design, conduct and reporting considerations. Nat. Rev. Drug. Discov. 18, 797–807 (2019).
Google Scholar
van der Velden, D. L. et al. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature 574, 127–131 (2019).
Google Scholar
Wang, S. et al. Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours. BMJ Open 11, e044543 (2021).
Google Scholar
Zheng, R., Wang, S., Zhao, G., Wei, W. & Li, N. Rare tumor list provide vast opportunities for novel drug development in China. Sci. Bull. 70, 132–134 (2025).
Google Scholar
Wang, S. et al. Comprehensive genomic profiling of rare tumors: Routes to targeted therapies. Front. Oncol. 10, 536 (2020).
Google Scholar
Wang, S. et al. Comprehensive genomic profiling of rare tumors in China: Routes to immunotherapy. Front. Immunol. 12, 631483 (2021).
Google Scholar
Wang, S. et al. An overview of cancer drugs approved through expedited approval programs and orphan medicine designation globally between 2011 and 2020. Drug Discov. Today 27, 1236–1250 (2022).
Google Scholar
Zhou, J. et al. First report: PLATFORM Study for precision treatment of rare tumors in China. Cancer Lett. 597, 217021 (2024).
Google Scholar
